关于2024年半年度业绩说明会召开情况的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实、准确和完整承担法律责任。 汉商集团股份有限公司（以下简称"公司"）于 2024 年 8 月 22 日 15:00- 16:00 通过证券时报·e 公司（https://www.egsea.com/live/list.html）举行 了 2024 年半年度业绩说明会。现将说明会情况公告如下： 证券代码：600774 股票简称：汉商集团 编号：2024-051 汉商集团股份有限公司 1 优势？ 一、本次业绩说明会召开情况 关于本次说明会的召开事项，公司已于 2024 年 8 月 16 日在《中国证券报》 《上海证券报》《证券时报》《证券日报》及上海证券交易所网站上披露了《汉商 集团股份有限公司关于召开 2024 年半年度业绩说明会的公告》（公告编号 2024- 049）。 2024 年 8 月 22 日 15:00-16:00，公司副董事长杜书伟先生、总裁杨芳女士、 独立董事车桂娟女士、副总裁兼财务总监、董事会秘书张镇涛先生出席了本次说 明会。公司人员与投资者进行了互动交流和 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 625,954,926.08, a decrease of 10.74% compared to CNY 701,235,971.12 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was CNY 8,510,842.71, down 82.35% from CNY 48,208,382.08 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was CNY -4,084,336.32, a decline of 111.25% compared to CNY 36,309,150.46 in the same period last year[14]. - The net cash flow from operating activities was CNY 86,016,942.03, a decrease of 35.86% from CNY 134,113,987.01 in the previous year[14]. - Basic earnings per share for the first half of 2024 were CNY 0.0288, a decrease of 82.37% from CNY 0.1634 in the same period last year[15]. - The weighted average return on net assets was 0.5068%, a decrease of 2.35 percentage points from 2.8532% in the previous year[15]. - The company reported a total non-operating income and expenses of 131,770.65, excluding government subsidies[17]. - The company achieved operating revenue of 625.95 million yuan in the first half of 2024, a decrease of 10.74% year-on-year, down 75.28 million yuan[22]. - The net profit attributable to shareholders was 8.51 million yuan, a significant decline of 82.35% compared to the same period last year, down 39.70 million yuan[22]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,530,538,582.32, down 4.45% from CNY 3,694,821,482.47 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company were CNY 1,683,604,883.76, an increase of 0.51% from CNY 1,675,094,041.05 at the end of the previous year[14]. - The company's cash and cash equivalents decreased by 39.67% compared to the previous year, totaling ¥86,252,147.14[25]. - Total current assets decreased from ¥714,346,005.70 to ¥591,145,230.33, a decrease of around 17.2%[61]. - The total liabilities as of the end of the reporting period were CNY 994,629,103.55, compared to CNY 957,638,035.47 at the end of the previous year, showing an increase of about 3.9%[66]. - The total equity attributable to shareholders was CNY 1,729,931,280.11, slightly down from CNY 1,746,522,991.50 in the previous year, indicating a decrease of approximately 1.0%[66]. Market Position and Strategy - The company has over 90 pharmaceutical products for sale, focusing on digestive, respiratory, and anti-infection areas[17]. - The main products include Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules, which are critical for treating various conditions[17]. - The company follows a "production based on sales" model, ensuring production plans align with market demand and inventory levels[17]. - The company is positioned to benefit from the rapid development of the pharmaceutical industry in China, driven by recent healthcare reforms[17]. - The company is committed to the dual business strategy of "big health + big commerce" to drive growth in the pharmaceutical and medical device sectors[17]. - The company aims to enhance its product pipeline in medical devices by focusing on R&D breakthroughs and patent reserves related to absorbable materials[18]. - The company plans to expand its self-organized exhibition scale to increase revenue from the exhibition operations segment, leveraging the recovery of the market economy in 2024[19]. Research and Development - The company is advancing its research in assisted reproductive technologies, with AID and IVF techniques at a leading level domestically[21]. - The company is committed to technological innovation, with its DDCI-01 project having completed Phase I clinical trials and currently undergoing Phase IIa trials for rare diseases[20]. - The company has completed the asset transfer and management system setup for Dongfang Pharmaceutical, with three products launched in the market during the reporting period[22]. - The company has significant risks related to macroeconomic fluctuations and policy changes[29]. - New drug research and development requires significant investment and carries high risks, which may impact long-term growth if not effectively managed[30]. Environmental Responsibility - The company has received a pollution discharge permit valid for five years, with major pollutants including wastewater, waste gas, and noise[35]. - The wastewater treatment process at the subsidiary meets the required standards for discharge, ensuring compliance with environmental regulations[38]. - Dikan Pharmaceutical has been recognized as a "Good Environmental Protection Enterprise" in Sichuan Province in 2022, reflecting its commitment to environmental responsibility[43]. - The company has implemented measures to reduce carbon emissions, including energy-saving initiatives and improvements in production processes to enhance energy efficiency[44]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 21,023[55]. - The largest shareholder, Wuhan Hanyang Investment Development Group Co., Ltd., holds 79,444,603 shares, representing 26.93% of the total shares[56]. - The second-largest shareholder, Zall Holdings Co., Ltd., holds 47,539,995 shares, representing 16.11% of the total shares[56]. - The third-largest shareholder, Yan Zhi, holds 44,254,715 shares, representing 15.00% of the total shares[56]. Accounting and Compliance - The financial statements were approved by the board on August 15, 2024[86]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[90]. - The company uses a 12-month operating cycle for liquidity classification of assets and liabilities[92]. - The company recognizes revenue based on actual transactions and events, in accordance with relevant accounting standards[89]. - The company recognizes lease liabilities at the present value of future lease payments, using the interest rate implicit in the lease or the incremental borrowing rate[150]. Inventory and Receivables Management - The ending inventory balance is RMB 212,183,568.57, with a decrease from the beginning balance of RMB 235,466,560.60, reflecting a reduction of approximately 9.8%[181]. - The total accounts receivable at the end of the period is CNY 161,373,375.91, with a bad debt provision of CNY 21,106,919.28, representing a provision ratio of 13.09%[166]. - The company has a significant amount of bad debt provisions, with CNY 2,687,452.61 accounted for individually and CNY 158,685,923.30 accounted for collectively, indicating a focus on managing credit risk[165]. - The aging analysis shows that 98.44% of the bad debt provision is related to receivables over three years old, highlighting potential collection challenges[165]. Future Outlook - The company plans to leverage the recovery of the consumer market to enhance its commercial exhibition sector through new establishments or acquisitions[22]. - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[76].

证券代码：600774 证券简称：汉商集团 公告编号：2024-048 汉商集团股份有限公司 2024年半年度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 汉商集团股份有限公司（以下简称"公司"）根据《上海证券交易所上市公 司自律监管指引第3号-行业信息披露-第四号-零售》《上海证券交易所上市公司 自律监管指引第3号-行业信息披露-第六号-医药制造》等相关规定，现将2024 年半年度主要经营数据披露如下： 一、报告期内公司主营业务分行业、分产品经营情况 （一）主营业务分行业情况 单位：元 币种：人民币 | | | | 主营业务分行业情况 | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行 | 营业收入 | 营业成本 | 毛利率 | 营业收入比上 | 营业成本比上 | 毛利率比上 | | 业 | | | （%） | 年增减（%） | 年增减（%） | 年增减（%） | | 药品 | 429,740,014.81 | 239,483,351.26 | 4 ...

证券代码：600774 证券简称：汉商集团 公告编号：2024-049 汉商集团股份有限公司 关于召开 2024 年半年度业绩说明会的公告 投资者可于 2024 年 8 月 16 日(星期五)至 8 月 21 日(星期三)16:00 前通过公司邮箱 hshsd@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 汉商集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 16 日发布公 司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度 经营成果、财务状况，公司计划于 2024 年 8 月 22 日 15:00-16:00 举行 2024 年 半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

证券代码：600774 股票简称：汉商集团 编号：2024-047 汉商集团股份有限公司 关于部分董监高以及管理人员增持公司股份计划实施完成 暨增持结果的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实、准确和完整承担法律责任。 1 姓名 职务 拟增持金额区 间（万元） 已完成增持金 额（万元） 增持数量 （股） 杜书伟 副董事长 200-300 200.07 292,900 杨芳 董事兼总裁 50-60 52.04 72,800 魏泽清 常务副总裁 25-35 25.53 31,500 张燕萍 副总裁 25-35 27.91 40,000 肖萍 副总裁 20-25 20.05 27,600 冯帆 副总裁 10-20 10.00 14,100 张镇涛 副总裁、总会计师、董秘 50-60 50.66 78,000 龙舟 副总裁 30-35 30.04 39,400 王冠南 副总裁 50-60 51.94 91,000 刘静涛 监事 10-20 10.01 14,200 曾宪钢 总裁助理 10-20 10.13 15,000 三、增持计划实施进展情况 | 姓名 | ...

证券代码：600774 股票简称：汉商集团 编号：2024-046 汉商集团股份有限公司 关于重大资产重组进展公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实、准确和完整承担法律责任。 一、本次交易基本情况 汉商集团股份有限公司（以下简称"公司"）拟通过发行股份的方式向卓尔 国际商业管理武汉合伙企业（有限合伙）、正安资产（开曼群岛）实业股份有限 公司购买其持有的正安实业（武汉）有限公司 100%股权，拟通过发行股份及支付 现金的方式向卓尔城投资发展有限公司购买其持有的"武汉客厅项目经营性资 产"，同时，向不超过 35 名特定对象发行股份募集配套资金（以下简称"本次 交易"）。本次交易预计构成重大资产重组，构成关联交易，不构成重组上市。 二、本次交易的历史披露情况 根据上海证券交易所（以下简称"上交所"）相关规定，经公司申请，公司 股票自 2023 年 8 月 18 日开市起停牌，具体内容详见公司于 2023 年 8 月 18 日 在上交所网站（www.sse.com.cn）披露的《汉商集团股份有限公司筹划重大资产 重组停牌公告》（公告编号：2023-026）。 ...

证券代码：600774 证券简称：汉商集团 公告编号：2024-045 汉商集团股份有限公司 关于控股股东增持股份比例达到 1% 暨增持计划实施完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增持计划的主要内容：汉商集团股份有限公司（以下简称"本公司"或"公司"） 控股股东卓尔控股有限公司（以下简称"卓尔控股"）计划自 2024 年 2 月 7 日起 6 个月内， 通过《中华人民共和国证券法》及中国证券监督管理委员会、上海证券交易所的相关规定允 许的方式增持公司股份。增持股份的数量或比例：拟累计增持股份数量为截止公告日公司总 股本的 1%。 增持计划的实施情况：卓尔控股于 2024 年 4 月 29 日至 2024 年 7 月 16 日期间通 过上海证券交易所交易系统以集中竞价交易方式累计增持公司股票 2,950,400 股，占公司 已发行股份的 1.00%，累计增持金额 21,492,838.00 元，本次增持计划实施完毕。 公司于 2024 年 7 月 16 日收到卓尔控股《关于增持汉商集团股份 ...

Financial Performance - The company expects a net profit attributable to shareholders of approximately 8 million yuan for the first half of 2024, a decrease of about 40.21 million yuan compared to the same period last year, representing a year-on-year decline of approximately 83.41%[4] - The expected net profit attributable to shareholders, after deducting non-recurring gains and losses, is projected to be around -4.5 million yuan, a decrease of about 40.81 million yuan compared to the same period last year, indicating a year-on-year decline of approximately 112.39%[4] - In the first half of 2023, the company achieved a net profit attributable to shareholders of 48.21 million yuan, with a net profit of 36.31 million yuan after deducting non-recurring gains and losses[4] Factors Affecting Performance - The decline in performance is primarily attributed to the impact of the main business, including reduced profits from subsidiaries due to centralized procurement and rising raw material prices[5] - The subsidiary Chongqing Dikang Traditional Chinese Medicine Co., Ltd. experienced lower sales revenue in the first half of the year due to resuming operations, coupled with high fixed costs[6] - The commercial sector's profitability has declined, contributing to the overall reduction in profits[6] Market Recovery - The exhibition sector has seen a gradual market recovery, resulting in profits increasing compared to the same period last year[6] Forecast and Caution - The company emphasizes that the performance forecast is based on preliminary calculations and has not been audited by registered accountants[3] - Investors are advised to be cautious as the forecast data is subject to change and the final financial data will be disclosed in the official half-year report[3] - The company has not identified any significant uncertainties that could impact the accuracy of this performance forecast[3]

证券代码：600774 股票简称：汉商集团 编号：2024-043 根据《问询函》的相关要求，公司会同本次重大资产重组的相关各方就《问 询函》中所提问题进行了认真的核查、分析和研究，逐项予以落实和回复，并对 重大资产重组预案及其摘要等文件进行了补充和修订，具体内容详见公司于 2023 年 9 月 21 日披露的《关于上海证券交易所对汉商集团股份有限公司发行股 份及支付现金购买资产并募集配套资金暨关联交易预案问询函的回复公告》（公 告编号：2023-039）、《汉商集团股份有限公司发行股份及支付现金购买资产并募 集配套资金暨关联交易预案（修订稿）》、《汉商集团股份有限公司发行股份及支 付现金购买资产并募集配套资金暨关联交易预案（摘要）（修订稿）》等相关公告。 2023 年 9 月 21 日、2023 年 10 月 24 日、2023 年 11 月 23 日、2023 年 12 月 23 日、2024 年 1 月 23 日，公司对本次重大资产重组的进展情况进行了披露，具 汉商集团股份有限公司（以下简称"公司"）拟通过发行股份的方式向卓尔 国际商业管理武汉合伙企业（有限合伙）、正安资产（开曼群岛）实业股份有限 公司 ...

证券代码：600774 股票简称：汉商集团 编号：2024-042 汉商集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 汉商集团股份有限公司（以下简称"汉商集团"或"公司"）控股股东卓尔控股有 限公司（以下简称"卓尔控股"）及其一致行动人阎志先生，截至本公告披露日，合计 持有公司股份 91,794,710 股，占公司总股本的 31.11%。本次部分股份解除质押后，卓 尔控股及其一致行动人阎志先生累计质押公司股份 55,500,000 股，占合计持有公司股 份的 60.46%，占公司总股本的 18.81%。 2、控股股东资信状况良好，将通过自有资金、银行贷款、股票分红、对外投资收 益等多种途径获得还款来源。 公司于 2024 年 6 月 18 日收到公司控股股东卓尔控股《关于汉商集团股份解押的通 知》。现将相关情况公告如下： | 股东名称 | 卓尔控股有限公司 | 阎志 | 合计 | | --- | --- | --- | --- | | 本次解质股份（股） ...